Top Biosensors Companies

Biosensors Market size was valued at USD 32.72 Billion in 2024 and is poised to grow from USD 35.37 Billion in 2025 to USD 65.95 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026–2033).

The global biosensors market is highly competitive, with numerous players in the market. An instance of a strategic partnership within the biosensors marketplace is the collaboration among the Abbott Laboratories and Bigfoot Biomedical. The two companies collaborated to develop and commercialize a diabetes management system that combines Abbott's FreeStyle Libre glucose-sensing technology with Bigfoot Biomedical's insulin delivery systems. The aim of the collaboration was to develop a simple and user-friendly solution for diabetics, combining continuous glucose monitoring (CGM) with automatic insulin delivery to create a permissive system. Abbott expertise in biosensors and glucose monitoring, paired with Bigfoot's innovation in insulin management. This strategic partnership, which could dramatically improve patients' lives by providing diabetes management facilitates and enhances glucose monitoring. 'Abbott Laboratories (USA) ', 'Roche Diagnostics (Switzerland) ', 'Medtronic plc (Ireland) ', 'Bio-Rad Laboratories, Inc. (USA) ', 'DuPont (USA) ', 'Biosensors International Group, Ltd. (Singapore) ', 'Cytiva (UK) ', 'Dexcom, Inc. (USA) ', 'Lifescan IP Holdings, LLC (USA) ', 'Masimo Corporation (USA) ', 'Nova Biomedical (USA) ', 'Universal Biosensors (Australia) ', 'ACON Laboratories, Inc. (USA) ', 'CARDEA BIO INC. (USA) ', 'Conductive Technologies (USA) ', 'EarlySense (Israel) ', 'Innovative Sensor Technology IST AG (Switzerland) ', 'LifeSignals (USA) ', 'NeuroSky (USA) ', 'SD Biosensor, INC. (South Korea)'

The biosensors market is driven by the growing demand for point-of-care (POC) assays, especially in the healthcare industry. Biosensors enable rapid, accurate and portable assays, essential for monitoring chronic diseases, managing acute conditions, and responding to public health emergencies. POC testing and its efficiency leads to its adoption in various settings, from clinical to home care, thereby boosting biosensors market growth. 

Increasing Device Deployment for Diabetes Monitoring: The prevalence of diabetes and associated complications is increasing in populations worldwide because of its high prevalence, most people demand early diagnosis and surveillance. Biosensors enable accurate diagnosis and monitoring of treatment and treatment efficacy in diabetic patients due to their precise advantages, such as accurate insulin estimation, cost, and utilization. According to an article published in 2023 by MDPI, traditional analytical methods for insulin detection are time-consuming, expensive, and lack real-time monitoring capabilities, as these factors can lead to production inspection at the point of view and continuous monitoring. 

North America is the dominant region in the global biosensors market. North America held the largest revenue share of over 39.60% in 2023 owing to the presence of key populations and rise in targeted diseases during the forecast period, technological advancements, that the introduction of small diagnostic tools that increase the penetration of electronic medical records into the market. Additionally, the Clean Air Act, Clean Water Act and National Environmental Policy Act all exist in the US. and is expected to boost the regional market.